Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. (ONC) submitted a Form 144 proposing the sale of 89,794 ADS through Morgan Stanley Smith Barney LLC on NASDAQ, showing an aggregate market value of $25,869,651.40 and 54,564,278 ADS outstanding. The approximate sale date is 08/13/2025.
The filing states the ADS were acquired on 08/13/2025 by exercise of stock options from the issuer and paid in cash. It also lists prior common-share sales by Xiaobin Wu in June 2025: 1,363 (6/23/2025) for $354,380.00, 630 (6/17/2025) for $158,047.22, 1,543 (6/16/2025) for $409,694.43, and 1,934 (6/06/2025) for $489,590.94. The notice includes the standard representation that the filer does not possess undisclosed material adverse information.
BeOne Medicines Ltd. (ONC) filed a Form 144 disclosing a proposed sale of 10,338 ADS on NASDAQ with an aggregate market value of $2,978,377.80. The filing shows those ADS were acquired partly by an exercise of stock options (9,226 ADS, cash paid on 08/13/2025) and partly as restricted stock units (1,112 ADS on 06/05/2025). The notice lists 54,564,278 shares outstanding, and the proposed block represents a very small portion of outstanding shares.
The filing also discloses recent sales by the same seller over the past three months: 2,042 common shares sold on 07/30/2025, 06/16/2025 and 06/06/2025 for combined gross proceeds of $571,975.61. This Form 144 is a regulatory notice of intent to sell and records the means of acquisition and prior dispositions.
BeOne Medicines (ONC) – Form 4 insider activity
Chief Financial Officer Aaron Rosenberg reported a mandatory tax-related sale of 1,190 American Depositary Shares (ADS) on 08/01/2025 at $290.47 per ADS, generating roughly $0.35 million in proceeds. Each ADS represents 13 ordinary shares. The disposition was executed automatically to cover withholding taxes triggered by the vesting of a restricted share-unit (RSU) grant. One-quarter of the RSU award vests annually on 31 July through 2028, with accelerated vesting possible upon certain termination events.
No derivative securities were exercised or disposed of in this filing. After the transaction, Rosenberg directly owns 215,332 ordinary shares and 0 ADS, meaning the shares sold equal about 7 % of his reported equity stake. The filing shows continued equity alignment through ongoing RSU vesting, while the share sale itself may be viewed as a routine liquidity event rather than an indicator of fundamental outlook.
BeOne Medicines Ltd. (ONC) – Form 4 filing dated 31-Jul-2025
SVP & General Counsel Henry Chan Lee reported a mandatory tax-related sale of 920 American Depositary Shares (ADS) on 30-Jul-2025 at a weighted-average price of $304.6008. Each ADS equals 13 ordinary shares, so the transaction represents the disposition of roughly 11,960 ordinary shares equivalent.
The ADS were automatically sold to cover withholding taxes upon vesting of a previously granted RSU award that vests 25 % annually on the anniversary of 29-Jul-2022, with possible acceleration on certain termination events. Following the sale, Lee continues to hold 266,474 ordinary shares directly.
- No derivative security activity was reported.
- The filing was executed by attorney-in-fact Qing Nian.
The transaction appears routine and driven by tax-withholding obligations rather than discretionary selling, limiting its market significance.